+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 0 - 17Years
All Genders
ID05582993

Evaluating Vonicog Alfa rVWF for Prevention of Bleeding in Children with Severe Von Willebrand Disease

Led by Takeda · Updated on 2026-09-09

24

Participants Needed

23

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of vonicog alfa, a recombinant von Willebrand factor rVWF, as a prevention treatment for children diagnosed with severe Von Willebrand Disease VWD. This Phase 3 study includes children who have previously been treated with VWF products or plasma-derived VWF pdVWF. The study is designed to assess how well vonicog alfa works over a 12-month treatment period. Participants are divided into three age groups under 6 years, 6 to under 12 years, and 12 to under 18 years. Each group will receive vonicog alfa by intravenous infusion twice weekly at an initial dose between 40 to 60 international units per kilogram IUkg. Treatment may also include ADVATE infusions as needed for bleeding episodes or surgical bleeding management. The treatment period lasts for 12 months with regular dosing and monitoring. During the study, participants will visit the clinic five times after starting treatment. Researchers will monitor bleeding rates, safety events, antibody development, vital signs, and blood levels of vonicog alfa and related factors. The main measure is the annualized bleeding rate during prophylactic treatment. Other assessments include adverse events, infusion details, and laboratory tests over the 12-month period to evaluate treatment impact and safety.

CONDITIONS

Brief Title

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

Research Team

T

Takeda Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here